Plastoquinone A Decyl Triphenylphosphonium bromide (Vizomitin) eye drops – [5 ml vial]

Description

Vizomitin Pharmacodynamics
Plastoquinonyldecyltriphenylphosphonium bromide (PDTP) is a derivative of plastoquinone which is linked to the triphenylphosphine residue through the linker chain (C10). PDTP at low (nanomolar) concentrations exhibits high antioxidant activity. It also has a stimulating effect on the process of tear production, epithelization, and contributes to the stability of the tear film.
One of the reasons for the development of age-related cataract is the damaging effect of ultraviolet radiation, which initiates photo-oxidation processes leading to the denaturation of the crystalline lens basic structural component. The first defense of the eye tissues against UV radiation is the tear fluid, which absorbs UV light in the 240-320 nm range and neutralizes it due to components of the antioxidant activity of the tear fluid. According to preclinical studies, the anticataractic effect of Vizomitin® is associated with an increase in the expression level of the main lens proteins ?-crystallins, restoration of the lens epithelium and activation of energy processes in it. According to clinical study data, patients with age-related cataract who used Visomitin® showed an increase in tear antioxidant activity.

Indications
-Dry eye syndrome.
-Initial stage of age-related cataract.

Contraindications
Hypersensitivity to the components of the drug, age under 18 years.
PREGNANCY AND LACTATION
No adequate controlled studies have been performed in pregnant and nursing women. It is not recommended to prescribe the drug during pregnancy. If it is necessary to prescribe during lactation, breastfeeding should be discontinued for the period of treatment.

Directions for use and dosages

• Dry eye syndrome: 1-2 drops of the drug in the conjunctival sac 3 times a day. The duration of the treatment course is determined by the doctor depending on the disease severity.
• Initial stage of age-related cataract: 1-2 drops of the drug in the conjunctival sac 3 times a day. Duration of treatment course is 6 months. Observation of an ophthalmologist is necessary during the drug therapy in order to assess the degree of disease progression and necessity to continue conservative therapy.